The first issue of UR Ventures Technology Review is out and available here.
The 17 June installment of the Good Advice: Case Studies in Clinical Research, Regulation, and the Law will examine the fascinating history of the COX-2 litigation. Presented by M. Kerry O’Banion, MD, PhD and Thomas Jackson, JD and Immediate Past President of the University of Rochester, this session promises to get to the heart of the story.
See the event listing for more information.
Camber NeuroTherapeutics Inc., founded based on discoveries made in the laboratories of Harris “Handy” A. Gelbard, M.D., Ph.D. and Stephen Dewhurst, Ph.D., plans to attack the cognitive component of neurodegenerative diseases using a completely new approach: stopping the inflammation in the brain, so-called neuroinflammation, that impairs the function of nerve cells and the vast networks they create. These neural networks allow us to store and recall memories, plan and prioritize, focus on particular tasks, and process sensory information.
Rochester, NY – May 15, 2015 – EagleDream Health, Inc., a healthcare analytics software solutions company today announced it has acquired Focused Medical Analytics, LLC, (FMA) a company specializing in data analysis to identify, understand, and address clinical variation. The acquisition strengthens EagleDream Health’s analytics solution designed to provide both broad and deep access to clinical, financial, claims and patient generated health data that enables measurement of clinical quality and outlines areas of cost reduction across the health care continuum.
17 April 2015 CNN Money
Panther Biotechnology, Inc. (OTC PINK: PBYA), a biotechnology company specializing in the development of enhanced therapeutics for the treatment of neoplastic disorders, is pleased to announce today that it has entered into an exclusive global license agreement with the University of Rochester.
Outstanding young talents and innovative thinkers from all disciplines up to 35 years of age are invited to apply for an opportunity to present their research project, business plan, entrepreneurial or social initiative that is relevant to the world today — in 3 minutes!
The SPARK Entrepreneurs club is holding a 24-hour Red Paperclip Challenge for students at all levels of study from Friday, March 20 to Saturday, March 21. Event registration starts at 6:00 p.m. on Friday in the Rettner Hall atrium. The event will kick off with an introduction about the Challenge, ice-breakers, and optional brainstorming sessions. Over the next 24 hours, SPARK e-board members will take shifts operating the table in Rettner, where they will be offering free coffee and help for participants. The Rettner screen will display a live Twitter feed of the teams’ documented trade transactions. At 6:00 p.m. the following night, all participants will return and present their final item to three judges. Three winners will be selected and awarded cash prizes. The event will close with food, networking, and live DJing from WRUR. Watch the trailer and pre-register on Facebook.
Research that has transformed scientists’ understanding of the brain and neurodegenerative diseases like Alzheimer’s has been awarded the 2014 Newcomb Cleveland Prize of the American Association for the Advancement of Science (AAAS).
The Association’s oldest honor, the prize annually recognizes the author or authors of an outstanding paper published in the journal Science, and will be awarded this year for a study that appeared in the October 2013 edition of journal, entitled “Sleep Drives Metabolite Clearance from the Adult Brain.” The prize will be presented on Friday, February 13, at the AAAS Annual Meeting in San Jose, California.
Amy Or, Wall Street Journal, 17 December 2014
Norwest Venture Partners’ portfolio company iCardiac Technologies Inc. may have a way to help pharmaceutical companies detect which experimental drugs might flat line over cardiac concerns.
The Rochester, N.Y.-based company recently completed a study in collaboration with the U.S. Food and Drug Administration which demonstrated that cardiac toxicity in drugs can be detected much earlier in the development process than previously thought by medical professionals.